NCT04544813View on ClinicalTrials.gov

A Study of JNJ-77474462 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

October 13, 2020

Primary Completion Date

May 30, 2021

Study Completion Date

May 30, 2021

Conditions
Healthy
Interventions
DRUG

JNJ-77474462

Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).

DRUG

Anakinra

Participants will receive a SC injection of anakinra 100 mg once daily for 3 days.

Trial Locations (1)

4006

Nucleus Network, Q-Pharm Pty Ltd, Herston

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04544813 - A Study of JNJ-77474462 in Healthy Participants | Biotech Hunter | Biotech Hunter